Pagerduty, Inc.
$998.39M- Market cap
- $1.05B
- Debt
- +$420.61M
- Cash
- −$469.84M
Capital structure 71% equity / 29% debt · EV / Revenue 2.03x · EV / EBITDA 24.82x
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2025 ·
Decision snapshot: PD stock price at discount vs IONS $13.32 current versus $62.54 implied using P/S multiple.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at IONS's multiple
Implied fair value · at PD's multiple
Snapshot Sep 8, 2026, 4:00 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth lag
Pricing power
Operating leverage
Multiple discount
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: PD FY 2026 (ended Jan 31, 2026) · IONS FY 2025 (ended Dec 31, 2025). Fiscal years are not aligned.
Trendline
Nine period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
Market cap plus debt, less cash.
Capital structure 71% equity / 29% debt · EV / Revenue 2.03x · EV / EBITDA 24.82x
Capital structure 81% equity / 19% debt · EV / Revenue 9.53x
IONS carries the larger enterprise value at $8.99B against $998.39M; PD trades on the lower EV / Revenue multiple (2.03x vs 9.53x).
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
PAGERDUTY, INC. · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Ionis Pharmaceuticals, Inc. · implied price per share
Latest annual free cash flow must be positive to qualify the filing-backed baseline.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Debt / equity
Total debt against shareholders' equity
1.66x
4.59x
Net debt / EBITDA
Leverage against operating earnings
-1.22x
1.34x
Cash and equivalents
Liquid reserves on the balance sheet
$469.84M
$2.68B
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
Atlassian Corp
PD vs TEAM
Gitlab Inc.
PD vs GTLB
Elastic N.V.
PD vs ESTC
Dynatrace, Inc.
PD vs DT
ServiceNow, Inc.
PD vs NOW
Sarepta Therapeutics, Inc.
PD vs SRPT
Moderna, Inc.
PD vs MRNA
Natera, Inc.
PD vs NTRA
ILLUMINA, INC.
PD vs ILMN
AMGEN INC
PD vs AMGN
VERTEX PHARMACEUTICALS INC / MA
PD vs VRTX
$420.61M
$2.24B
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.